Research programme: cell based therapeutics - Endonovo Therapeutics

Drug Profile

Research programme: cell based therapeutics - Endonovo Therapeutics

Latest Information Update: 16 Aug 2016

Price : $50

At a glance

  • Originator National Aeronautics and Space Administration
  • Developer Endonovo Therapeutics
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Graft-versus-host disease

Most Recent Events

  • 10 Aug 2016 Endonovo files for patent protection with United States patent and Trademark Office (USPTO) for production of biologics for treating chemical and radiation injuries in USA
  • 10 Aug 2016 Endonovo has patent protection for "Use of electromagnetic stimulation of cells to produce biological molecules" in USA
  • 29 Jun 2016 Endonovo Therapeutics files for continuation patent protection for production of the adult stem cell secretome in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top